IL1B and metabolic dysfunction-associated steatohepatitis: In the NASH mouse model, treatment with schisandrin B (17) or kukoamine B (18) downregulated TNF-α, IL-1β and IL-6 levels (Leong et al., 2016; Zhao Q. et al., 2020).